Richard Chesworth

6.7k citations

32 papers · 2.4k indexed · 2 hit papers · h-index 17

Co-authors: Robert A. Copeland Mikel P. Moyer Roy M. Pollock Margaret Porter Scott Victoria M. Richon Christina J. Allain Alejandra Raimondi Christine R. Klaus
Topics: Cancer-related gene regulation (17 papers)Epigenetics and DNA Methylation (16 papers)Acute Myeloid Leukemia Research (3 papers)
Cited by: Molecular Biology Hematology Pathology and Forensic Medicine
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Blood
Partner nations: United States United Kingdom Japan

In The Last Decade

Richard Chesworth

30 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

2013 581 citations Sarah K. Knutson, Natalie M. Warholic et al. profile →
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

2013 546 citations Scott R. Daigle, Edward J. Olhava et al. Blood profile →

Peers

Countries citing papers authored by Richard Chesworth

Since Specialization

Citations

This map shows the geographic impact of Richard Chesworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Chesworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Chesworth more than expected).

Fields of papers citing papers by Richard Chesworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Chesworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Chesworth. The network helps show where Richard Chesworth may publish in the future.

Co-authorship network of co-authors of Richard Chesworth

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Chesworth. A scholar is included among the top collaborators of Richard Chesworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Chesworth. Richard Chesworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of a peptide inhibitor for the histone methyltransferase WHSC1 2018 ·PLoS ONE ·Michael J. Morrison,P. Ann Boriack‐Sjodin,Kerren K. Swinger,Tim J. Wigle,(unknown),Kevin W. Kuntz,Margaret Porter Scott,William P. Janzen,Richard Chesworth,Kenneth W. Duncan,(unknown),John W. Lampe,Lorna H. Mitchell,Robert A. Copeland	22
2	Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models 2017 ·Molecular Cancer Therapeutics ·Elayne Chan-Penebre,Kelli Armstrong,Allison E. Drew,Alexandra Grassian,Igor Feldman,Sarah K. Knutson,Kristy Kuplast‐Barr,Maria Roche,John Campbell,Peter Ho,Robert A. Copeland,Richard Chesworth,J. Joshua Smith,Heike Keilhack,Scott Ribich	127
3	Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models 2017 ·Cancer Research ·Allison E. Drew,(unknown),John E. Campbell,Cuyue Tang,J. Joshua Smith,Richard Chesworth,Robert A. Copeland,Alejandra Raimondi,Scott Ribich	3
4	Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human 2015 ·Cancer Chemotherapy and Pharmacology ·Nigel J. Waters,Sherri Smith,Edward J. Olhava,Kenneth W. Duncan,Richard D. E. Burton,(unknown),(unknown),Roy M. Pollock,Mikel P. Moyer,Richard Chesworth	23
5	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening 2015 ·SLAS DISCOVERY ·Tim J. Wigle,Kerren K. Swinger,John E. Campbell,Michael D. Scholle,John Sherrill,(unknown),P. Ann Boriack‐Sjodin,Kevin W. Kuntz,Richard Chesworth,Mikel P. Moyer,Margaret Porter Scott,Robert A. Copeland	31
6	Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652 2015 ·Drug Metabolism and Disposition ·Nathalie Rioux,Lorna H. Mitchell,Philip R. Tiller,(unknown),(unknown),(unknown),Scott Ribich,Mikel P. Moyer,Robert A. Copeland,Richard Chesworth,Nigel J. Waters	5
7	Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor 2015 ·Xenobiotica ·Nathalie Rioux,Kenneth W. Duncan,(unknown),Xiu‐Sheng Miao,Elayne Chan-Penebre,Mikel P. Moyer,Michael J. Munchhof,Robert A. Copeland,Richard Chesworth,Nigel J. Waters	16
8	Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound 2015 ·ACS Medicinal Chemistry Letters ·Lorna H. Mitchell,Allison E. Drew,Scott Ribich,Nathalie Rioux,Kerren K. Swinger,Suzanne L. Jacques,Trupti Lingaraj,P. Ann Boriack‐Sjodin,Nigel J. Waters,Tim J. Wigle,Oscar Moradei,Lei Jin,Thomas V. Riera,(unknown),Mikel P. Moyer,J. Joshua Smith,Richard Chesworth,Robert A. Copeland	95
9	Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666 2015 ·ACS Medicinal Chemistry Letters ·Kenneth W. Duncan,Nathalie Rioux,P. Ann Boriack‐Sjodin,Michael J. Munchhof,Lawrence A. Reiter,Christina R. Majer,Lei Jin,L. Danielle Johnston,Elayne Chan-Penebre,(unknown),Margaret Porter Scott,Roy M. Pollock,Nigel J. Waters,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Richard Chesworth	103
10	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity 2015 ·ACS Medicinal Chemistry Letters ·John E. Campbell,Kevin W. Kuntz,Sarah K. Knutson,Natalie M. Warholic,Heike Keilhack,Tim J. Wigle,Alejandra Raimondi,Christine R. Klaus,Nathalie Rioux,Akira Yokoi,Satoshi Kawano,Yukinori Minoshima,Hyeong-Wook Choi,Margaret Porter Scott,Nigel J. Waters,J. Joshua Smith,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland	94
11	Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors 2015 ·Molecular Cancer Therapeutics ·Nathalie Rioux,Heike Keilhack,Blythe Thomson,Richard Chesworth,Robert A. Copeland,Eric Hedrick,Peter Ho,Nigel J. Waters	2
12	Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor 2014 ·Biopharmaceutics & Drug Disposition ·Aravind Basavapathruni,Edward J. Olhava,Scott R. Daigle,(unknown),Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,(unknown),Victoria M. Richon,Roy M. Pollock,Robert A. Copeland,Mikel P. Moyer,Richard Chesworth,Paul G. Pearson,Nigel J. Waters	64
13	Potent inhibition of DOT1L as treatment of MLL-fusion leukemiabreakdown → 2013 ·Blood ·Scott R. Daigle,Edward J. Olhava,(unknown),Aravind Basavapathruni,Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Nigel J. Waters,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Roy M. Pollock	546
14	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L 2012 ·Chemical Biology & Drug Design ·Aravind Basavapathruni,Lei Jin,Scott R. Daigle,Christina R. Majer,(unknown),Tim J. Wigle,Kevin W. Kuntz,Richard Chesworth,Roy M. Pollock,Margaret Porter Scott,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Edward J. Olhava	114
15	Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia. 2012 ·Blood ·Roy M. Pollock,Scott R. Daigle,(unknown),Aravind Basavapathruni,Lei Jin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Edward J. Olhava	3
16	EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors 2011 ·Neuropharmacology ·Jos Prickaerts,Nick P. van Goethem,Richard Chesworth,Gideon Shapiro,Frank Boess,Christoph Methfessel,(unknown),Dorothy G. Flood,Dana Hilt,Maria S. Gawryl,Sonia Bertrand,Daniel Bertrand,Gerhard König	174
17	Neuronal Store-Operated Calcium Entry Pathway as a Novel Therapeutic Target for Huntington's Disease Treatment 2011 ·Chemistry & Biology ·Jun Wu,(unknown),V. A. Vigont,Lori Hrdlicka,(unknown),Carol M. Singh,(unknown),Richard Chesworth,Gideon Shapiro,O. A. Zimina,Xuesong Chen,Qingqing Wu,Л. Н. Глушанкова,Michael K. Ahlijanian,Gerhard Koenig,G. N. Mozhayeva,Еlena Kaznacheyeva,Ilya Bezprozvanny	127
18	P3‐295: Pharmacokinetic and pharmacodynamic analysis of the gamma‐secretase modulator (GSM) EVP‐0015962 2010 ·Alzheimer s & Dementia ·Kevin M. Felsenstein,(unknown),Zhiyong Yang,(unknown),(unknown),Scott Nolan,(unknown),Winnie Lee,Lori Hrdlicka,(unknown),Faris Albayya,Zhiming Tu,Holger Patzke,Richard Chesworth,Gideon Shapiro,(unknown),Michael K. Ahlijanian,Gerhard Koenig,(unknown)	4
19	Discovery and Development of Novel HDAC Inhibitors for Huntington’s Disease 2008 ·Neurotherapeutics ·Holger Patzke,Richard Chesworth,(unknown),(unknown),(unknown),Jessica Smith,F. Huet,Gideon Shapiro,(unknown),Pierre Beaulieu,(unknown),(unknown),(unknown),Sarah J Nevitt,(unknown),(unknown),(unknown),Michael K. Ahlijanian,(unknown)	1
20	Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists 2004 ·Bioorganic & Medicinal Chemistry Letters ·Richard Chesworth,Michael P. Zawistoski,Bruce A. Lefker,Kimberly O. Cameron,(unknown),(unknown),Robert L. Rosati,(unknown),Donna N. Petersen,Amy Brault,(unknown),Lydia C. Pan,(unknown),(unknown),(unknown),Thomas A. Owen,Thomas A. Brown,David D. Thompson,Paul DaSilva‐Jardine	32

About Richard Chesworth

Richard Chesworth is a scholar working on Molecular Biology, Hematology and Toxicology, having authored 32 papers that have together received 2.4k indexed citations. Recurring topics across this work include Cancer-related gene regulation (17 papers), Epigenetics and DNA Methylation (16 papers) and Acute Myeloid Leukemia Research (3 papers). The work is most often cited by research in Molecular Biology (2.1k citations), Hematology (223 citations) and Pathology and Forensic Medicine (192 citations). Richard Chesworth has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Robert A. Copeland, Mikel P. Moyer, Roy M. Pollock, Margaret Porter Scott, Victoria M. Richon, Christina J. Allain, Alejandra Raimondi, Christine R. Klaus, Tim J. Wigle and Kevin W. Kuntz. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact